These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 22430749

  • 1. [Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience].
    Pistillucci G, Sciacca V, Ciorra A, Di Palma T, Calabretta F, Lugini A, Rossi R, D'Aprile M, Veltri E.
    Recenti Prog Med; 2012 Feb; 103(2):62-5. PubMed ID: 22430749
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M.
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
    Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ, Korean Cancer Study Group.
    Cancer; 2012 Dec 15; 118(24):6234-42. PubMed ID: 22674612
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
    Lee HY, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, Kim HT, Ryoo HM, Bae SH, Lee SS, Choi K, Hong DS, Lee KH, Kwon JH, Choi IS, Kim BS, Lee NS, Gong SJ, Park K.
    Lung Cancer; 2009 Dec 15; 66(3):338-43. PubMed ID: 19299031
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
    Zugazagoitia J, Puente J, González-Larriba JL, Manzano A, Sotelo M, Hernández S, Sanz J, Pérez P, Díaz-Rubio E.
    Oncology; 2013 Dec 15; 84(5):255-64. PubMed ID: 23428780
    [Abstract] [Full Text] [Related]

  • 14. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S.
    Chemotherapy; 2010 Dec 15; 56(6):472-7. PubMed ID: 21099219
    [Abstract] [Full Text] [Related]

  • 15. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.
    Gridelli C, Di Maio M.
    Expert Opin Pharmacother; 2010 Feb 15; 11(2):321-4. PubMed ID: 20053140
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Pemetrexed salvage chemotherapy for NSCLC: implementation study].
    Jungels C, Berghmans T, Meert AP, Lafitte JJ, Scherpereel A, Sculier JP.
    Rev Mal Respir; 2012 Jan 15; 29(1):21-7. PubMed ID: 22240216
    [Abstract] [Full Text] [Related]

  • 18. Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer.
    Xu B, Liu P, Yin Y, Liu P, Shu Y.
    Biomed Pharmacother; 2013 Oct 15; 67(8):763-9. PubMed ID: 23790249
    [Abstract] [Full Text] [Related]

  • 19. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ, Yang PC.
    Lung Cancer; 2011 Oct 15; 74(1):132-8. PubMed ID: 21367480
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS.
    Jpn J Clin Oncol; 2009 Jan 15; 39(1):27-32. PubMed ID: 18952704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.